<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954068</url>
  </required_header>
  <id_info>
    <org_study_id>3008</org_study_id>
    <nct_id>NCT02954068</nct_id>
  </id_info>
  <brief_title>IV Versus IM Administration of Oxytocin for Postpartum Bleeding</brief_title>
  <official_title>Intravenous Versus Intramuscular Administration of Oxytocin and Its Relationship With Postpartum Bleeding and Other Clinical Signs: a Randomized Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Rosarino de Estudios Perinatales (CREP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <brief_summary>
    <textblock>
      This double-blind, randomized controlled trial will evaluate the effect of the route of
      administration of 10 IU of oxytocin on the average blood loss postpartum. Participants will
      be randomized to receive 10 IU of oxytocin by IV infusion or 10 IU of oxytocin by injection
      IM
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of blood loss (mL)</measure>
    <time_frame>1 hour postpartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of women who had postpartum blood loss ≥500 ml</measure>
    <time_frame>1 hour postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of women who had postpartum blood loss ≥1000 ml</measure>
    <time_frame>1 hour postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change in hemoglobin level</measure>
    <time_frame>pre-delivery and at least 24 hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time required until expulsion of the placenta</measure>
    <time_frame>1 hour postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion who needed additional Interventions</measure>
    <time_frame>Through study completion, an average of 24-48 hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>1 hour postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>15, 30, 45 and 60 minutes postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>15, 30, 45 and 60 minutes postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>IV Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Oxytocin + IM placebo</intervention_name>
    <arm_group_label>IV Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Oxytocin + IV placebo</intervention_name>
    <arm_group_label>IM administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  She is present to give birth to a live fetus

          -  Vaginal delivery

          -  Willing to participate in the study

          -  Able to give informed consent

        Exclusion Criteria:

          -  Scheduled for a cesarean

          -  Reject the placement of an IV during labor (for intravenous infusion)

          -  Cannot give informed consent for any reason

          -  Not willing and / or cannot answer questions about background
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilana Dzuba, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Carroli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Rosarino de Estudios Perinatales (CREP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Durocher</last_name>
    <phone>2124481230</phone>
    <email>jdurocher@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital J.R. Vidal</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carroli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
